Michael T. Lotze, professor of surgery, immunology and bioengineering at the Pitt School of Medicine, was honored with the 2021 Society for Immunotherapy of Cancer Lifetime Achievement Award at the group’s 36th annual meeting last month in Washington D.C.
Lotze is currently chief cellular therapy officer of Nurix Therapeutics and scientific advisory council chair for the Alliance for Cancer Gene Therapy.
He is widely regarded as the leader in exploring cancer as a disorder of cell death and is devising novel strategies to approach the disease in this context. He initiated the first approved gene therapy protocols at the National Institutes of Health and has treated more than 100 patients on gene therapy protocols at the University of Pittsburgh. He is the co-inventor of 10 patents in dendritic cell vaccines and antigen discovery, and author of more than 500 scientific papers and chapters in basic and applied tumor immunology and cytokine biology.
Society for Immunotherapy of Cancer is a member-driven organization dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy through educational programs that foster scientific exchange and collaboration. Learn more at www.sitcancer.org.